Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Manufacturing (cGMP) deviations

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards.

1,754 FDA drug recalls with this cause, newest first.

This category covers departures from current Good Manufacturing Practice during production. It is FDA's broadest label, used when a facility's own process control failed somewhere along the line even if no single ingredient was proven unsafe on its own. Where the report names a specific consequence - a temperature excursion, a contaminant, a potency problem - we file the recall under that more specific cause instead; what remains here is the genuinely general case.

Class II · Moderate risk

Back Pain-Off

cGMP deviations

Terminated cGMP deviation Ultra Seal Corporation NDC 47682-073-00 D-0476-2022
Class II · Moderate risk

Ephedrine Plus

cGMP deviations

Terminated cGMP deviation Ultra Seal Corporation NDC 65193-320-24 D-0473-2022
Class II · Moderate risk

Chloresin

cGMP deviations

Terminated cGMP deviation Ultra Seal Corporation NDC 51532-0107-2 D-0468-2022
Class II · Moderate risk

Proctofoam HC

cGMP deficiencies

Terminated cGMP deviation Mylan Pharmaceuticals Inc NDC 0037-6822-10 D-0452-2022
Class II · Moderate risk

Lexette (halobetasol propionate)

CGMP Deviation: Difficulty dispensing/does not dispense or dispensing liquid instead of foam.

Ongoing cGMP deviation Mayne Pharma Inc NDC 51862-604-50 D-0387-2022
Class II · Moderate risk

Phenol

CGMP Deviations

Terminated cGMP deviation Edge Pharma, LLC NDC 05446-1211-03 D-0443-2022